Revolution Medicines’ stock has surged on the promise of a pancreatic-cancer drug. With any deal to buy the firm looking unlikely, investors should be prepared for the long haul. WSJ's Aaron Back ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results